S. Liang

Most-cited papers

1. Chinese guidelines related to novel coronavirus pneumonia

   T. Qiu, S. Liang, M. Dabbous, Yi-Tong Wang +2 more

   2020Journal of Market Access & Health Policy48 citations Open access

   Semantic Scholar

   Save

2. The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects

   Tingting Qiu, Yi-Tong Wang, S. Liang, Ru Han +1 more

   2021Drug Discovery Today17 citations Open access

   Semantic Scholar

   Save

3. Gene Therapy Evidence Generation and Economic Analysis: Pragmatic Considerations to Facilitate Fit-for-Purpose Health Technology Assessment

   T. Qiu, M. Pochopień, S. Liang, G. Saal +3 more

   2022Frontiers in Public Health14 citations Open access

   Semantic Scholar

   Save

4. Challenges in the market access of regenerative medicines, and implications for manufacturers and decision-makers: a systematic review.

   T. Qiu, M. Pochopień, E. Hanna, S. Liang +4 more

   2022Regenerative medicine11 citations

   Semantic Scholar

   Save

5. Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers

   T. Qiu, S. Liang, Yi-Tong Wang, C. Dussart +2 more

   2021Frontiers in Public Health7 citations Open access

   Semantic Scholar

   Save

6. An Overview of Cell and Gene Therapy Development in China

   Yi-Tong Wang, T. Qiu, S. Liang, M. Toumi

   2021Human Gene Therapy6 citations

   Semantic Scholar

   Save

7. Current state of developing advanced therapies for rare diseases in the European Union

   T. Qiu, Yi-Tong Wang, M. Dabbous, E. Hanna +3 more

   20205 citations

   Semantic Scholar

   Save

8. Chinese Clinical Studies for Pharmacological Treatments of Coronavirus Disease 2019 (COVID-19)

   Ru Han, Yi-Tong Wang, M. Dabbous, S. Liang +2 more

   20205 citations Open access

   Semantic Scholar

   Save

9. Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials

   Yi-Tong Wang, S. Liang, T. Qiu, Ru Han +3 more

   2020medRxiv5 citations Open access

   Semantic Scholar

   Save

10. COVID-19: Why SOLIDARITY and DisCoVeRy trials may fail to bring informative and timely results

    M. Toumi, S. Liang, M. Dabbous, Yi-Tong Wang +2 more

    2020medRxiv4 citations Open access

    Semantic Scholar

    Save

11. Management guidelines for preventing exposure to antineoplastics.

    W. Liu, Zi-Yang Wu, T. Sun, S. Liang +7 more

    2023Chinese journal of cancer research = Chung-kuo yen cheng yen chiu2 citations Open access

    Semantic Scholar

    Save

12. Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach

    Ru Han, S. Liang, C. François, S. Aballéa +2 more

    2021Journal of Market Access & Health Policy1 citations Open access

    Semantic Scholar

    Save

13. Partnership agreements for regenerative medicines: a database analysis and implications for future innovation.

    T. Qiu, Yi-Tong Wang, S. Liang, Ru Han +1 more

    2021Regenerative medicine1 citations

    Semantic Scholar

    Save

14. A critical analysis and review of Lancet COVID-19 hydroxychloroquine study

    M. Toumi, Małgorzata Biernikiewicz, S. Liang, Yi-Tong Wang +2 more

    2020Journal of Market Access & Health Policy1 citations Open access

    Semantic Scholar

    Save

15. PNS40 The Implementation of Volume-Based Drug Procurement Policy in China

    Yi-Tong Wang, S. Liang, E. Hanna, T. Qiu +1 more

    20200 citations Open access

    Semantic Scholar

    Save

16. What Makes the UK Recovery Trial More Pragmatic than the European Discovery Trial?

    Ru Han, S. Liang, M. Biernikiewicz, Yi-Tong Wang +1 more

    20200 citations Open access

    Semantic Scholar

    Save